Dendritic cell vaccine - Argos Therapeutics/Pharmstandard

Drug Profile

Dendritic cell vaccine - Argos Therapeutics/Pharmstandard

Alternative Names: AGS003-like therapy

Latest Information Update: 07 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Argos Therapeutics Inc
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Renal cell carcinoma

Most Recent Events

  • 05 Feb 2018 Argos Therapeutics enters into an option agreement to license anti-PD1 monoclonal antibodies from Pharmstandard and Actigen
  • 05 Feb 2018 Pharmacodynamics data from a preclinical study in Renal cell carcinoma released by Argos Therapeutics
  • 18 Nov 2016 Preclinical trials in Renal cell carcinoma in USA and Russia (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top